WuXi AppTec (OTCMKTS:WUXAY) & Aspira Women’s Health (NASDAQ:AWH) Head-To-Head Review

WuXi AppTec (OTCMKTS:WUXAY) and Aspira Women’s Health (NASDAQ:AWH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares WuXi AppTec and Aspira Women’s Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
WuXi AppTec	N/A	N/A	N/A
Aspira Women’s Health	-199.77%	-396.38%	-119.23%

Institutional & Insider Ownership

31.9% of Aspira Women’s Health shares are held by institutional investors. 4.9% of Aspira Women’s Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares WuXi AppTec and Aspira Women’s Health’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WuXi AppTec	N/A	N/A	N/A	N/A	N/A
Aspira Women’s Health	$8.18 million	7.17	-$27.17 million	($12.42)	-0.46

WuXi AppTec has higher earnings, but lower revenue than Aspira Women’s Health.

Analyst Recommendations

This is a summary of recent recommendations for WuXi AppTec and Aspira Women’s Health, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WuXi AppTec	0	0	1	0	3.00
Aspira Women’s Health	0	1	1	0	2.50

Aspira Women’s Health has a consensus price target of $17.80, suggesting a potential upside of 209.57%. Given Aspira Women’s Health’s higher probable upside, analysts plainly believe Aspira Women’s Health is more favorable than WuXi AppTec.

About WuXi AppTec

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

About Aspira Women’s Health

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering. Its product pipeline includes OvaWatch, a non-invasive blood-based risk assessment test to determine ovarian cancer risk for patients with an adnexal mass; and Endocheck, an in-development non-invasive blood test designed as an aid in the identification of endometriosis for patients with suspected endometriosis earlier in their prognosis journey. In addition, the company operates Aspira Synergy, a testing platform and cloud service; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.